Abstract:2059 Background: Our previous study showed A2B5+ glioma stem-like cell lysate-loaded DC vaccine (GSC-DCV) extended survival in recurrent GBM. Additionally, our earlier research indicates that A2B5+ GSCs, enriched with tumor-specific antigens like URGCP, have the potential to activate CD8+ T cells via dendritic cell antigen presentation. Recent research on recurrent GBM suggest aPD-1 mAb neoadjuvant therapy further extends survival. This study is intended to assess the safety and efficacy of this combined therapeutic approach. Methods: Patients with recurrent GBM (IDH1/2 -) post-radiotherapy and chemotherapy were enrolled. All patients received aPD-1 mAbs before surgery. Post-surgery, patients were randomly assigned to the monotherapy arm (aPD-1 mAbs and placebo) or combination therapy arm (aPD-1 mAbs and GSC-DCV), with treatments given every 3-6 weeks until disease progression or intolerable toxicity. The primary endpoint was OS, and secondary endpoints included PFS and trAEs. Results: A total of 21 patients were randomly assigned to the monotherapy (n=11) and combination therapy (n=10) arms. Patient characteristics were well-balanced. The monotherapy arm had a median OS of 8.2 months, while the combination arm showed a significantly longer OS of 22.7 months (HR, 0.2774; 95% CI, 0.0828 to 0.9291, P=0.0376). Multivariate Cox model analysis confirmed the independent prognostic impact of the combination therapy on patients with recurrent GBM (HR, 9.911; 95% CI, 1.520 to 64.623; P=0.016). There was no statistically significant difference in PFS between the two arms. Notably, patients in the combination group experienced a substantial improvement in post-progression survival (PPS) compared to the monotherapy group (7.8 m vs. 1.4 m; P=0.0266). The long survival benefit observed in the combination group was associated with continuous treatment, as cessation led to short-term tumor progression. Subgroup analysis based on tumor burden revealed that the combination therapy was significantly more effective in the low tumor burden cohort (mOS: 23.2 vs. 9.6 months; P=0.0162). No significant difference was observed in the monotherapy group between the two cohorts. High URGCP expression was significantly positively associated with OS in patients undergoing combination therapy (R2=0.8608, P=0.0061). Grade 1-2 trAEs were reported in 27.3% of patients in the monotherapy arm and 50.0% in the combination therapy arm. No grade 3 or higher trAEs occurred. Conclusions: The combination therapy has proven to be safe and well-tolerated. Although there was no significant improvement in PFS, patients achieved a sufficiently long OS benefit compared to the monotherapy arm. Notably, the combination therapy was particularly effective in patients with a low tumor burden through long-term, multi-course treatment. Clinical trial information: NCT04888611 .

Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma

Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma

DDEL-08. NOVEL COMBINATION THERAPY USING PI3KINASE INHIBITION AND IMMUNE BASED THERAPY FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME

OS12.6.A Combination therapy of CAR-NK-cells and anti-PD-1 results in high efficacy against advanced-stage glioblastoma in a syngeneic mouse model and induces protective anti-tumor immunity in vivo

CTIM-07. PHASE IIB RANDOMIZED, BLINDED, CONTROLLED TRIAL EVALUATING NEOADJUVANT PD-1 BLOCKADE COMBINED WITH A2B5+ GLIOMA STEM-LIKE CELL LYSATE-LOADED DCV IN RECURRENT GLIOBLASTOMA (IDH1/2 -)- TRAIL IN PROGRESS

Ctim-28. Neoadjuvant Anti-Pd1 Immunotherapy For Surgically Accessible Recurrent Glioblastoma: Clinical And Molecular Outcomes Of A Stage 2 Single-Arm Expansion Cohort

Dddr-39. Pi3 Kinase And Checkpoint Inhibition: A Potentially Novel Therapeutic Strategy For Glioblastoma (Gbm)

IMMU-19. TARGETING GLIOBLASTOMA IMMUNOSUPPRESSION AND TREATMENT RESISTANCE WITH IBRUTINIB IN COMBINATION WITH STEREOTACTIC RADIATION AND IMMUNE CHECKPOINT BLOCKADE

CTIM-25. NEOADJUVANT ANTI-PD1 IMMUNOTHERAPY FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES OF A STAGE 2 SINGLE-ARM EXPANSION COHORT

NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma

Phase IIb Randomized, Blinded, Controlled Trial Evaluating Neoadjuvant PD-1 Blockade Combined with A2B5+ Glioma Stem-Like Cell Lysate-Loaded DC Vaccine in Recurrent Glioblastoma (IDH1/2 -).

Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential

Tmic-78. Chemotherapy Induced Immunogenic Response In Glioma And Implications For Therapeutic Strategies

IMMU-07. COMBINED PD1 AND LAG3 INHIBITION IN PRECLINICAL MODELS AND PATIENTS WITH DNA REPLICATION REPAIR DEFICIENT GLIOBLASTOMA (RRD-GBM): AN IRRDC STUDY

Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment

Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma

Ctim-27. Doc1021 Cell-Based Vaccination As Adjuvant Therapy For Glioblastoma: Phase I Clinical Trial Analysis

Combination immunotherapy strategies for glioblastoma

501 Systemic Immunological Suppression in Glioblastoma Is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq) From a Randomized Controlled Trial

Therapeutic efficacy of an immune stimulatory gene therapy strategy in a mouse model of high grade brainstem glioma